SCHEMBL3096007

SCHEMBL3096007

N#Cc1c(NCC(O)CO)nc2scc(N)c2c1-c1cc2ccccc2o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 3/20 0.39
NPC1 O15118 6/20 0.36
RAB9A P51151 6/20 0.36
MAPT P10636 5/20 0.36
KCNA5 P22460 1/20 0.35
KCNH2 Q12809 1/20 0.35
SMN1; SMN2 Q16637 5/20 0.34
STAT1 P42224 1/20 0.34
ALDH1A1 P00352 3/20 0.34
NFKB1 P19838 3/20 0.34
NFKB2 Q00653 3/20 0.34
RELA Q04206 3/20 0.34
KDM4E B2RXH2 2/20 0.34
TP53 P04637 2/20 0.33
EEF2K O00418 1/20 0.33
IKBKB O14920 1/20 0.32
CHEK1 O14757 1/20 0.32
CDK1 P06493 1/20 0.32
MKNK1 Q9BUB5 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095668 0.88 ADORA1 (0.46) ADORA1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL3098350 0.86 ADORA1 (0.41) ADORA1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL3101670 0.84 EEF2K (0.51) ADORA1MAPTALDH1A1EEF2KIKBKB
SCHEMBL3099045 0.83 NPC1 (0.39) ADORA1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL3654079 0.81 ADORA1 (0.40) ADORA1MAPTKCNA5KCNH2ALDH1A1
SCHEMBL3090605 0.80 KDM4E (0.47) ADORA1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL3088349 0.72 EEF2K (0.54) ADORA1MAPTALDH1A1EEF2KIKBKB
SCHEMBL3090569 0.71 RAB9A (0.52) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3101500 0.71 EEF2K (0.53) ADORA1ALDH1A1KDM4EEEF2KIKBKB
SCHEMBL3096017 0.70 NPC1 (0.42) ADORA1NPC1RAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202882-B2 5-cyanothienopyridines for the treatment of tumours MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-06-19 US disclosed
US-20100234369-A1 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234369-A1 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS TGFBR1, TGFBR2, ACVR1 ADORA1 106/4885NPC1 3806/4885RAB9A 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.